Piper Sandler downgraded Inari from Overweight to Neutral and set a new price target of $55.00 from $85.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $75.00 | Outperform | Oppenheimer |
| 9/18/2024 | $50.00 | Hold | Stifel |
| 9/3/2024 | $47.00 | Market Perform | Leerink Partners |
| 8/9/2024 | $68.00 | Buy | Deutsche Bank |
| 7/25/2024 | Outperform | William Blair | |
| 7/18/2024 | Buy → Hold | Needham | |
| 2/29/2024 | $85.00 → $55.00 | Overweight → Neutral | Piper Sandler |
| 1/23/2024 | $72.00 | Buy | Needham |
4/A - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)